%0 Journal Article
%T Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study.
%A Krawczyk N
%A Lim S
%A Cherian T
%A Goldfeld KS
%A Katyal M
%A Rivera BD
%A McDonald R
%A Khan M
%A Wiewel E
%A Braunstein S
%A Murphy SM
%A Jalali A
%A Jeng PJ
%A Kutscher E
%A Khatri UG
%A Rosner Z
%A Vail WL
%A MacDonald R
%A Lee JD
%J Drug Alcohol Depend
%V 261
%N 0
%D 2024 Jun 24
%M 38924958
%F 4.852
%R 10.1016/j.drugalcdep.2024.111377
%X <B>BACKGROUND: </B>Offering medications for opioid use disorder (MOUD) in carceral settings significantly reduces overdose. However, it is unknown to what extent individuals in jails continue MOUD once they leave incarceration. We aimed to assess the relationship between in-jail MOUD and MOUD continuity in the month following release.<BR><B>METHODS: </B>We conducted a retrospective cohort study of linked NYC jail-based electronic health records and community Medicaid OUD treatment claims for individuals with OUD discharged from jail between 2011 and 2017. We compared receipt of MOUD within 30 days of release, among those with and without MOUD at release from jail. We tested for effect modification based on MOUD receipt prior to incarceration and assessed factors associated with treatment discontinuation.<BR><B>RESULTS: </B>Of 28,298 eligible incarcerations, 52.8 % received MOUD at release. 30 % of incarcerations with MOUD at release received community-based MOUD within 30 days, compared to 7 % of incarcerations without MOUD (Risk Ratio: 2.62 (2.44-2.82)). Most (69 %) with MOUD claims prior to incarceration who received in-jail MOUD continued treatment in the community, compared to 9 % of those without prior MOUD. Those who received methadone (vs. buprenorphine), were younger, Non-Hispanic Black and with no history of MOUD were less likely to continue MOUD following release.<BR><B>CONCLUSIONS: </B>MOUD maintenance in jail is strongly associated with MOUD continuity upon release. Still, findings highlight a gap in treatment continuity upon-reentry, especially among those who initiate MOUD in jail. In the wake of worsening overdose deaths and troubling disparities, improving MOUD continuity among this population remains an urgent priority.